Mylan set to market generic Prilosec; Welsh get cancer meds as NICE debates;

> Mylan got the final FDA nod to make a generic version of the AstraZeneca heartburn drug Prilosec. Report

> Patients in Wales needing kidney cancer drugs that are yet to be approved by the organisation set up to appraise new medicines, will receive them on the NHS in the meantime. Report

> The European Medicines Agency recommended a new heart-risk contraindication for Orion's breast-cancer treatment Fareston, a drug GTx hopes to market in the U.S. to reduce side effects caused by a prostate-cancer treatment. Report

> Medication from genetically engineered animals could appear as early as next month if, as anticipated, the FDA approves ATryn, a blood thinner made from the milk of genetically engineered goats. Report

> York Pharma CEO and founder Terry Sadler will move to a new board position as president and founder, focusing on strategic direction and business development; Richard Anderson will take on CEO duties and Ian Miscampbell will be CFO. Report

> The U.K.'s Premier Research Group has signed a deal to buy the assets of fellow contract research organisation Pivotal Research Centers, a specialist in Phase I to IIa trials, for $4.75m. Report

> An experimental compound--sphingosine analog AAL-R--may be able to dampen part of the body's immune response to flu so infections can be fought without the "cytokine storm" that may cause the person to perish, a new study says. Report

> San Diego-based Akesis Pharmaceuticals is calling it quits, opting to file for Chapter 7 bankruptcy after anlayzing data from its sole remaining development program. Report

> Seattle Genetics has forged a special protocol agreement with the FDA for the pivotal study of SGN-35, an oncology drug. The biotech says that it plans to start the trial in the first quarter and hopes to gain an accelerated approval in 2011. Report

> Sweden's Biovitrum announced that it will spin out its small molecule subsidiary Cambridge Biotechnology (CBT). Report

> A consortium of global pharma companies backing Enlight Biosciences' hunt for new discovery and development technologies is announcing later this morning that it has added Johnson & Johnson to their ranks. Report

> Norway's Lytix Biopharma has ginned a $10.4 million funding round that will be spent on early-stage drug development. Lytix was established in 2003 by a group of scientists in the country working in the field of lytic peptides. Report

> The Bill and Melinda Gates foundation is leading a group of donors that has pledged a combined $635 million to renew the international campaign to eradicate polio, following an increase in polio cases that spread to seven other countries. Report

> Seattle-based PATH has been working on ways to improve the world's "cold chain," a long and fragile supply line that runs from manufacturers to villages and towns all around the world. Report

> Some areas around the country are reporting that an unprecedented effort to supply the U.S. with an improved flu vaccine is running into a wall of public indifference. Report

> Boston-based Vaccine Technologies (VTI) has inked a license and development agreement with Celldex Therapeutics. Report

And Finally... Vitamin D can help stave off the mental decline that can affect people in old age, a study has suggested. Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.